Knockdown of GSG2 inhibits the development and progression of non-small cell lung cancer in vitro and in vivo

References

• Siegel RL, Miller KD. Cancer statistics, 2019. A cancer journal for clinicians. 2019;69:7–34.
   PubMed Web of Science ®Google Scholar
• Naylor EC, Desani JK, Chung PK. Targeted therapy and immunotherapy for lung cancer. Surg Oncol Clin N Am. 2016;25:601–609.
   PubMed Web of Science ®Google Scholar
• Tessmer A, Kollmeier J. Treatment of advanced non-small-cell lung cancer with driver mutations. Deutsche Medizinische Wochenschrift 1946. 2015;140(5):140.
   Google Scholar
• Ko JL, Lin CH, Chen HC, et al. Effects and mechanisms of betulinic acid on improving EGFR TKI-resistance of lung cancer cells. Environmental toxicology. 2018;33:1153–1159.
   PubMed Web of Science ®Google Scholar
• Tanaka H, Yoshimura Y, Nozaki M, et al. Identification and characterization of a haploid germ cell-specific nuclear protein kinase (Haspin) in spermatid nuclei and its effects on somatic cells. J Biol Chem. 1999;274(24):17049–17057.
   PubMed Web of Science ®Google Scholar
• Higgins JM. The Haspin gene: Location in an intron of the integrin αE gene, associated transcription of an integrin αE-derived RNA and expression in diploid as well as haploid cells. Gene. 2001;267(1):55–69.
   PubMed Web of Science ®Google Scholar
• Yoshimura Y, Tanaka H, Nozaki M, et al. Nested genomic structure of haploid germ cell specific haspin gene. Gene. 2001;267:49–54.
   PubMed Web of Science ®Google Scholar
• Dai J, Sultan S, Taylor SS, et al. The kinase haspin is required for mitotic histone H3 Thr 3 phosphorylation and normal metaphase chromosome alignment. Genes Dev. 2005;19(4):472–488.
   PubMed Web of Science ®Google Scholar
• Wang F, Dai J, Daum JR, et al. Histone H3 Thr-3 phosphorylation by Haspin positions Aurora B at centromeres in mitosis. Science. 2010;330(6001):330.
   PubMed Web of Science ®Google Scholar
• Amoussou NG, Bigot A, Roussakis C, et al. Haspin: a promising target for the design of inhibitors as potent anticancer drugs. Drug Discov Today. 2018;23(2):409–415.
   PubMed Web of Science ®Google Scholar
• Huertas D, Soler M, Moreto J, et al. Antitumor activity of a small-molecule inhibitor of the histone kinase Haspin. Oncogene. 2012;31:1408–1418.
   PubMed Web of Science ®Google Scholar
• Martini M, De Santis MC, Braccini L, et al. PI3K/AKT signaling pathway and cancer: an updated review. Ann Med. 2014;46(6):372–383.
   PubMed Web of Science ®Google Scholar
• Jafari M, Ghadami E, Dadkhah T, et al. Pi3k/akt signaling pathway: erythropoiesis and beyond. J Cell Physiol. 2019;234(3):2373–2385.
   PubMed Web of Science ®Google Scholar
• Wu YL, Zhou C, Hu CP, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15(2):213–222.
   PubMed Web of Science ®Google Scholar
• Wang B, Jiang H, Wang L, et al. Increased MIR31HG lncRNA expression increases gefitinib resistance in non-small cell lung cancer cell lines through the EGFR/PI3K/AKT signaling pathway. Oncol Lett. 2017;13:3494–3500.
   PubMed Web of Science ®Google Scholar
• Tebbutt N, Pedersen MW, Johns TG. Targeting the ERBB family in cancer: Couples therapy. Nat Rev Cancer. 2013;13(9):663–673.
   PubMed Web of Science ®Google Scholar
• Cho BC, Chewaskulyong B, Lee KH, et al. Osimertinib versus Standard of Care EGFR TKI as first-line treatment in patients with EGFRm advanced NSCLC: FLAURA Asian subset. J Thorac Oncol. 2019;14(1):99–106.
   PubMed Web of Science ®Google Scholar
• Balboula AZ, Nguyen AL. Haspin kinase regulates microtubule-organizing center clustering and stability through Aurora kinase C in mouse oocytes. J Cell Sci. 2016;129(19):3648–3660.
   PubMed Web of Science ®Google Scholar
• Dai J, Kateneva AV, Higgins JM. Studies of haspin-depleted cells reveal that spindle-pole integrity in mitosis requires chromosome cohesion. J Cell Sci. 2009;122(22):4168–4176.
   PubMed Web of Science ®Google Scholar
• Higgins JM. Haspin: A newly discovered regulator of mitotic chromosome behavior. Chromosoma. 2010;119(2):137–147.
   PubMed Web of Science ®Google Scholar
• Barr FA, Sillje HH, Nigg EA. Polo-Like kinases and the orchestration of cell divisionreviews. Nat Rev Mol Cell Biol. 2004;5(6):429–440.
   PubMed Web of Science ®Google Scholar
• Carmena M, Earnshaw WC. The cellular geography of aurora kinases. Nat Rev Mol Cell Biol. 2003;4(11):842–854.
   PubMed Web of Science ®Google Scholar
• Champeris Tsaniras S, Kanellakis N, Symeonidou IE, et al. Licensing of DNA replication, cancer, pluripotency and differentiation: an interlinked world? Semin Cell Devl Biol. 2014;30:174–180.
   PubMed Web of Science ®Google Scholar
• Andrews PD, Knatko E, Moore WJ, et al. Mitotic mechanics: the auroras come into view. Curr Opin Cell Biol. 2003;15:672–683.
   PubMed Web of Science ®Google Scholar
• Schmit TL, Zhong W, Setaluri V, et al. Targeted depletion of polo-like kinase (Plk) 1 through lentiviral shRNA or a small-molecule inhibitor causes mitotic catastrophe and induction of apoptosis in human melanoma cells. J Invest Dermatol. 2009;129:2843–2853.
   PubMed Web of Science ®Google Scholar
• Inoki K, Li Y, Zhu T, et al. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol. 2002;4(9):648–657.
   PubMed Web of Science ®Google Scholar
• Holmes D. PI3K pathway inhibitors approach junction. Nat Rev Drug Discovery. 2011;10(8):563–564.
   PubMed Web of Science ®Google Scholar
• Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev. 2006;58(3):621–681.
   PubMed Web of Science ®Google Scholar
• Han L, Wang P, Sun Y, et al. Anti-Melanoma activities of haspin inhibitor CHR-6494 deployed as a single agent or in a synergistic combination with MEK inhibitor. J Cancer. 2017;8:2933–2943.
   PubMed Web of Science ®Google Scholar